These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34581402)

  • 1. Tick-borne encephalitis (TBE) in Switzerland: does the prolongation of vaccine booster intervals result in an increased risk of breakthroughs?
    Schmidt AJ; Altpeter E; Graf S; Steffen R
    J Travel Med; 2022 Mar; 29(2):. PubMed ID: 34581402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review.
    Steffen R; Erber W; Schmitt HJ
    Ticks Tick Borne Dis; 2021 Sep; 12(5):101779. PubMed ID: 34298356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule.
    Beran J; Douda P; Gniel D; Zent O
    Int J Med Microbiol; 2004 Apr; 293 Suppl 37():130-3. PubMed ID: 15146994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
    Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
    Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018.
    Baroutsou V; Zens KD; Sinniger P; Fehr J; Lang P
    Vaccine; 2020 Nov; 38(49):7825-7833. PubMed ID: 33164805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020.
    Zens KD; Haile SR; Schmidt AJ; Altpeter ES; Fehr JS; Lang P
    BMJ Open; 2022 Apr; 12(4):e061228. PubMed ID: 35459683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?
    Zent O; Plentz A; Schwarz TF; Frühwein N; Kuhr HB; Broeker M; Banzhoff A; Jilg W
    Vaccine; 2004 Dec; 23(3):312-5. PubMed ID: 15530673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety.
    Beran J; Xie F; Zent O
    Vaccine; 2014 Jul; 32(34):4275-80. PubMed ID: 24950352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of TBE vaccination in southern Germany and Latvia.
    Erber W; Khan F; Zavadska D; Freimane Z; Dobler G; Böhmer MM; Jodar L; Schmitt HJ
    Vaccine; 2022 Jan; 40(5):819-825. PubMed ID: 34952753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
    Wittermann C; Petri E; Zent O
    Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland.
    Zens KD; Baroutsou V; Sinniger P; Lang P
    PLoS One; 2021; 16(12):e0247216. PubMed ID: 34905534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
    Beran J; Lattanzi M; Costantini M; Pammolli A; Galgani I
    Vaccine; 2023 May; 41(23):3518-3524. PubMed ID: 37142462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults.
    Plentz A; Jilg W; Schwarz TF; Kuhr HB; Zent O
    Vaccine; 2009 Feb; 27(6):853-6. PubMed ID: 19071180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five year follow-up after primary vaccination against tick-borne encephalitis in children.
    Wittermann C; Izu A; Petri E; Gniel D; Fragapane E
    Vaccine; 2015 Apr; 33(15):1824-9. PubMed ID: 25728316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules.
    Costantini M; Callegaro A; Beran J; Berlaimont V; Galgani I
    Hum Vaccin Immunother; 2020 Sep; 16(9):2274-2279. PubMed ID: 31951780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule.
    Zent O; Jilg W; Plentz A; Schwarz TF; Frühwein N; Kuhr HB; Banzhoff A
    Vaccine; 2003 Dec; 21(32):4655-60. PubMed ID: 14585672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of tick-borne encephalitis (TBE)].
    Aebi C
    Ther Umsch; 2005 Nov; 62(11):726-30. PubMed ID: 16350534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.
    Beran J; Lattanzi M; Xie F; Moraschini L; Galgani I
    Vaccine; 2019 Jul; 37(32):4623-4629. PubMed ID: 29397225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of antibodies after vaccination against tick-borne encephalitis.
    Rendi-Wagner P; Zent O; Jilg W; Plentz A; Beran J; Kollaritsch H
    Int J Med Microbiol; 2006 May; 296 Suppl 40():202-7. PubMed ID: 16524776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.
    Schelling J; Einmahl S; Torgler R; Larsen CS
    Expert Rev Vaccines; 2024; 23(1):226-236. PubMed ID: 38288983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.